Oxurion Announces Top-Line Results from Part A of Phase II INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

By
Danielle Corrigan
-
0
191
Oxurion NV announced top-line results from Part A of its Phase II trial of THR-687, an integrin antagonist, for the treatment of DME.
[Oxurion NV]
Press Release